MapLight Therapeutics Prices $258.9M IPO; Anthropic Seen as More Sustainable AI Startup
Key Takeaways
- MapLight Therapeutics IPO priced at $17/share, raising $258.9M; Nasdaq debut on October 27.
- WSJ: Anthropic, backed by Amazon/Google, may be more sustainable than OpenAI despite data center costs.
- Health startup Tia cuts 23% of staff amid US health startup profitability challenges.
- Travel startups like Katanox and Jerne show growth with AI; investors focus on infrastructure.
- Coinbase plans to enable the entire startup lifecycle onchain for enhanced efficiency and transparency.
- Accel and Prosus partner to co-invest in early-stage Indian startups addressing systemic challenges.
- Cellcolabs secures $12M to scale GMP stem cell production, aiming for 90% cost reduction.
Top Stories
MapLight Therapeutics prices $258.9M IPO, Nasdaq debut imminent
On October 26, 2025, MapLight Therapeutics priced its IPO at $17 per share for 14.75 million shares, raising $258.9 million. Shares will begin trading on Nasdaq as MPLT on October 27, marking a significant startup funding milestone.
Anthropic seen as more sustainable AI startup than OpenAI
On October 26, 2025, The Wall Street Journal reported that Anthropic, backed by Amazon and Google, may have a clearer path to profitability than OpenAI despite heavy data center investments. This highlights evolving AI startup business models.
Tia cuts 23% staff amid US health startup profitability challenges
On October 26, 2025, Silicon Valley health startup Tia laid off 72 employees (23%) due to investor pressure for profitability, reflecting broader US health startup struggles with costs and sustainable business models.
Travel startups show growth, AI adoption, and investor focus shift
On October 27, 2025, PhocusWire reported travel startups like Katanox and Jerne achieved growth and partnerships, with AI increasingly vital. Investor focus is shifting toward infrastructure and experience-first travel models.
Coinbase aims to bring startup lifecycle fully onchain
On October 26, 2025, Coinbase CEO Brian Armstrong announced plans to enable the entire startup lifecycle onchain, enhancing capital formation efficiency and transparency in blockchain startups.
Accel and Prosus partner to co-invest in early-stage Indian startups
On October 26, 2025, Accel and Prosus announced a co-investment partnership targeting early-stage Indian startups addressing systemic challenges, expanding Accel's Atoms X program to support India's digital economy.
Cellcolabs secures $12M to scale GMP stem cell production
On October 27, 2025, Stockholm-based Cellcolabs raised $12 million from Titian Capital to advance industrial-scale GMP-certified mesenchymal stem cell production, aiming for 90% cost reduction by 2035 amid rising demand.